Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Diabetes, Type 2
Interventions
DRUG

Placebo

Tablets (n=6), 0 mg, once daily for 84 days

DRUG

150 mg PF-04991532

Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days

DRUG

450 mg PF-04991532

Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days

DRUG

750 mg PF-04991532

Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days

DRUG

Sitagliptin 100 mg

Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days

Trial Locations (44)

100

Pfizer Investigational Site, Taipei

710

Pfizer Investigational Site, Tainan City

1036

Pfizer Investigational Site, Budapest

11230

Pfizer Investigational Site, Brooklyn

22911

Pfizer Investigational Site, Charlottesville

27518

Pfizer Investigational Site, Cary

28401

Pfizer Investigational Site, Wilmington

29464

Pfizer Investigational Site, Mt. Pleasant

30094

Pfizer Investigational Site, Conyers

32216

Pfizer Investigational Site, Jacksonville

32901

Pfizer Investigational Site, Melbourne

33401

Pfizer Investigational Site, West Palm Beach

37620

Pfizer Investigational Site, Bristol

37660

Pfizer Investigational Site, Kingsport

40213

Pfizer Investigational Site, Louisville

43213

Pfizer Investigational Site, Columbus

44130

Pfizer Investigational Site, Guadalajara

44650

Pfizer Investigational Site, Guadalajara

53142

Pfizer Investigational Site, Kenosha

53209

Pfizer Investigational Site, Milwaukee

60607

Pfizer Investigational Site, Chicago

64460

Pfizer Investigational Site, Monterrey

72401

Pfizer Investigational Site, Jonesboro

72404

Pfizer Investigational Site, Jonesboro

75230

Pfizer Investigational Site, Dallas

77036

Pfizer Investigational Site, Houston

77074

Pfizer Investigational Site, Houston

77081

Pfizer Investigational Site, Houston

78229

Pfizer Investigational Site, San Antonio

90057

Pfizer Investigational Site, Los Angeles

92262

Pfizer Investigational Site, Palm Springs

02720

Pfizer Investigational Site, Fall River

02914

Pfizer Investigational Site, East Providence

02915

Pfizer Investigational Site, East Providence

R3E 3P4

Pfizer Investigational Site, Winnipeg

N7G 1Y7

Pfizer Investigational Site, Strathroy

L4J 8L7

Pfizer Investigational Site, Thornhill

M9W 4L6

Pfizer Investigational Site, Toronto

H7T 2P5

Pfizer Investigational Site, Laval

G6W 5M6

Pfizer Investigational Site, Saint Romuald

831 01

Pfizer Investigational Site, Bratislava

110-744

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01336738 - Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter